LOS ANGELES--(BUSINESS WIRE)--July 31, 2006--CytRx Corporation (Nasdaq:CYTR - News) today announced completion of the Phase I clinical trial of the novel HIV DNA + protein vaccine that it has exclusively licensed. Analysis of the unblinded data confirmed previous preliminary conclusions that the HIV vaccine formulation DP6-001 was generally well tolerated in volunteers receiving lower vaccine doses and was effective at eliciting both HIV-specific T-cell and antibody immune responses. A summary of the Phase I trial results will be filed with the U.S. Food and Drug Administration (FDA) in August 2006 and manuscripts that provide additional detailed results are being prepared to submit for publication in peer-reviewed journals and presentations at scientific conferences.
